Director, Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic
Ravulizumab’s Long-Term Efficacy and Safety as NMOSD Treatment: Sean Pittock, MD
May 2nd 2024The director for the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided an overview of the open-label extension of the phase 3 CHAMPION-NMOSD trial and how the newly approved ravulizumab fits with other NMOSD treatments. [WATCH TIME: 4 minutes]
Potential for Preventing NMOSD, Improving Access to Panel Testing: Sean Pittock, MD
May 18th 2023The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology provided commentary on the possibility of preventing NMOSD, and the need to improve access to approved therapies and AQP4 testing. [WATCH TIME: 3 minutes]
Success of Ravulizumab Through the Phase 3 CHAMPION-NMOSD Trial: Sean Pittock, MD
May 16th 2023The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed findings from the phase 3 CHAMPION-NMOSD trial of ravulizumab in patients with neuromyelitis optica spectrum disorder. [WATCH TIME: 5 minutes]
Technological Advancements Improving, Expanding Capabilities of Antibody Testing: Sean Pittock, MD
July 17th 2022The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the technological capabilities the center has, including the improved use of neural antibody testing. [WATCH TIME: 6 minutes]
Distinguishing and Diagnosing Various Presentations of Autoimmune Encephalitis: Sean Pittock, MD
July 5th 2022The director of the Mayo Clinic Center for Multiple Sclerosis and Autoimmune Neurology discussed the complexities in diagnosing autoimmune encephalitis and the approach needed to be taken. [WATCH TIME: 5 minutes]